CN1638759A - 包含双膦酸类化合物和cox－2抑制剂、用于治疗骨病的药物组合物 - Google Patents

包含双膦酸类化合物和cox－2抑制剂、用于治疗骨病的药物组合物 Download PDF

Info

Publication number
CN1638759A
CN1638759A CNA038049007A CN03804900A CN1638759A CN 1638759 A CN1638759 A CN 1638759A CN A038049007 A CNA038049007 A CN A038049007A CN 03804900 A CN03804900 A CN 03804900A CN 1638759 A CN1638759 A CN 1638759A
Authority
CN
China
Prior art keywords
cox
inhibitor
bis
phosphonic acids
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038049007A
Other languages
English (en)
Chinese (zh)
Inventor
Z·D·霍罗威茨
P·L·西蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1638759A publication Critical patent/CN1638759A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA038049007A 2002-02-28 2003-02-28 包含双膦酸类化合物和cox－2抑制剂、用于治疗骨病的药物组合物 Pending CN1638759A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0204756.1 2002-02-28
GBGB0204756.1A GB0204756D0 (en) 2002-02-28 2002-02-28 Organic compounds

Publications (1)

Publication Number Publication Date
CN1638759A true CN1638759A (zh) 2005-07-13

Family

ID=9932008

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038049007A Pending CN1638759A (zh) 2002-02-28 2003-02-28 包含双膦酸类化合物和cox－2抑制剂、用于治疗骨病的药物组合物

Country Status (9)

Country Link
US (1) US20050209198A1 (https=)
EP (1) EP1480637A1 (https=)
JP (1) JP2005523291A (https=)
CN (1) CN1638759A (https=)
AU (1) AU2003210386A1 (https=)
BR (1) BR0308105A (https=)
CA (1) CA2477347A1 (https=)
GB (1) GB0204756D0 (https=)
WO (1) WO2003072097A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107540726A (zh) * 2017-08-22 2018-01-05 河北科技大学 一类肽基塞来昔布衍生物及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
BR0213410A (pt) * 2001-10-19 2004-11-03 Novartis Ag Usos farmacêuticos de bisfosfonatos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107540726A (zh) * 2017-08-22 2018-01-05 河北科技大学 一类肽基塞来昔布衍生物及其应用

Also Published As

Publication number Publication date
AU2003210386A1 (en) 2003-09-09
BR0308105A (pt) 2005-01-04
US20050209198A1 (en) 2005-09-22
JP2005523291A (ja) 2005-08-04
EP1480637A1 (en) 2004-12-01
WO2003072097A1 (en) 2003-09-04
GB0204756D0 (en) 2002-04-17
CA2477347A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
CN1277545C (zh) 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途
CN1154490C (zh) 塞内昔布组合物
CN1202828C (zh) 二膦酸在制备抑制或逆转血管发生的药物中的用途
CA2345641A1 (en) A method for treating inflammatory diseases by administering a thrombin inhibitor
CN1512882A (zh) 包含cox-2抑制剂的可稀释配制的胃肠外组合物
CN1956706A (zh) 包含一种螯合剂的双膦酸酯肠溶固体口服剂型
CN1620300A (zh) 二膦酸盐的给药方法
CN1107364A (zh) 药物组合物
CN1671371A (zh) 芳香酶抑制剂和双膦酸酯的组合
JP2004521856A (ja) Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
CN1681515A (zh) 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法
CN1625405A (zh) 包含环加氧酶－2抑制剂和阿司匹林的组合
CN1703226A (zh) 用于治疗恶性疾病、包含双膦酸类化合物、cox－2抑制剂和紫杉醇的组合的药物组合物
CN1638759A (zh) 包含双膦酸类化合物和cox－2抑制剂、用于治疗骨病的药物组合物
CN1726030A (zh) 缬沙坦与cox－2抑制剂的组合
CN1826124A (zh) 用于治疗骨转移瘤、肿瘤生长和肿瘤诱导的骨丢失的组织蛋白酶k抑制剂和二膦酸盐/酯的组合
AU2002363089A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol
CN1771034A (zh) 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途
CN1756567A (zh) 体重增加抑制剂
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
CN1732004A (zh) 用jnk抑制剂治疗疼痛
CN1703218A (zh) 用于治疗疼痛的苯并噻二唑类化合物和cox－2抑制剂的组合
HK1067554A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor
HK1074787A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication